Intra-Cellular Therapies (NASDAQ:ITCI) Downgraded by Baird R W to Hold
Baird R W lowered shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) from a strong-buy rating to a hold rating in a research note released on Monday morning,Zacks.com reports. A number of other brokerages have also recently commented on ITCI. JPMorgan Chase & Co. increased their price target on Intra-Cellular Therapies from $81.00 to $89.00 […]
More Stories
Over-the-Counter Medicines, Other Items Recalled Over Feces Contamination: FDA
By Jack Phillips The U.S. Food and Drug Administration (FDA) late last week announced that a distributor is recalling its...
Iranian President Says His Country in ‘Full-Fledged War’ With US, Europe, and Israel
By Jack Phillips Iranian President Masoud Pezeshkian said Saturday that the Iranian regime is in a full-scale war with the...
US Airline Industry Caps a Strong 2025—What Lies Ahead in 2026
By Panos Mourdoukoutas Despite a shaky start earlier in the year, U.S. airline travel reached another milestone during the 2025...
What Trump’s National Security Strategy Means for Canada
By Noe Chartier Canada receives but a passing mention in the recently released U.S. National Security Strategy, but that doesn’t...
Italy Arrests 9 for Allegedly Using Charities to Fund Hamas Terrorists
By Tom Ozimek Italian authorities have arrested nine people on suspicion of financing Hamas through a network of charities operating...
Winter Weather Cancels Over 1,000 Flights Across US
By Jacki Thrapp Travelers may need to pack their patience on Dec. 27 as winter weather in the Northeast prompted...